183 related articles for article (PubMed ID: 16869816)
21. Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing.
Kloner RA; Jackson G; Hutter AM; Mittleman MA; Chan M; Warner MR; Costigan TM; Vail GM
Am J Cardiol; 2006 Jun; 97(12):1778-84. PubMed ID: 16765134
[TBL] [Abstract][Full Text] [Related]
22. Tadalafil is efficacious and well tolerated in the treatment of erectile dysfunction (ED) in men over 65 years of age: results from Multiple Observations in Men with ED in National Tadalafil Study in the United States.
Sharlip ID; Shumaker BP; Hakim LS; Goldfischer E; Natanegara F; Wong DG
J Sex Med; 2008 Mar; 5(3):716-25. PubMed ID: 18304286
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of tadalafil across ethnic groups and various risk factors in men with erectile dysfunction: Use of a novel noninferiority study design.
Morgentaler A; Barada J; Niederberger C; Donatucci C; Garcia CS; Natanegara F; Ahuja S; Wong DG
J Sex Med; 2006 May; 3(3):492-503. PubMed ID: 16681475
[TBL] [Abstract][Full Text] [Related]
24. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
Mallikaarjun S; Shoaf SE; Boulton DW; Bramer SL
Clin Pharmacokinet; 2008; 47(8):533-42. PubMed ID: 18611062
[TBL] [Abstract][Full Text] [Related]
25. Effects of tadalafil on erectile dysfunction in men with diabetes.
Sáenz de Tejada I; Anglin G; Knight JR; Emmick JT
Diabetes Care; 2002 Dec; 25(12):2159-64. PubMed ID: 12453954
[TBL] [Abstract][Full Text] [Related]
26. Five-year experience with tadalafil in the UK: an effective treatment for erectile dysfunction.
Dinsmore W
Int J Clin Pract; 2009 Aug; 63(8):1231-6. PubMed ID: 19624790
[TBL] [Abstract][Full Text] [Related]
27. Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist.
Bauman JW; Antal JM; Adams LM; Johnson BM; Murray SC; Peng B; Kirby LC; Lebowitz PF; Marbury TC; Swan S; Gutierrez M
Invest New Drugs; 2012 Apr; 30(2):662-71. PubMed ID: 21188466
[TBL] [Abstract][Full Text] [Related]
28. Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil.
Wrishko R; Sorsaburu S; Wong D; Strawbridge A; McGill J
J Sex Med; 2009 Jul; 6(7):2039-48. PubMed ID: 19453893
[TBL] [Abstract][Full Text] [Related]
29. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.
Boulton DW; Li L; Frevert EU; Tang A; Castaneda L; Vachharajani NN; Kornhauser DM; Patel CG
Clin Pharmacokinet; 2011 Apr; 50(4):253-65. PubMed ID: 21348538
[TBL] [Abstract][Full Text] [Related]
30. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women.
Jannuzzo MG; Poggesi I; Spinelli R; Rocchetti M; Cicioni P; Buchan P
Cancer Chemother Pharmacol; 2004 Jun; 53(6):475-81. PubMed ID: 15014897
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction.
Eardley I; Gentile V; Austoni E; Hackett G; Lembo D; Wang C; Beardsworth A
BJU Int; 2004 Oct; 94(6):871-7. PubMed ID: 15476525
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment.
de Zeeuw D; Remuzzi G; Kirch W
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S37-42. PubMed ID: 9331004
[TBL] [Abstract][Full Text] [Related]
33. The therapeutic dilemma: how to use tadalafil.
Carosa E; Lombardo F; Martini P; Brandetti F; Jannini EA
Int J Androl; 2005 Dec; 28 Suppl 2():74-80. PubMed ID: 16236070
[TBL] [Abstract][Full Text] [Related]
34. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
Schöller-Gyüre M; Kakuda TN; De Smedt G; Woodfall B; Berckmans C; Peeters M; Hoetelmans RM
Clin Ther; 2010 Feb; 32(2):328-37. PubMed ID: 20206790
[TBL] [Abstract][Full Text] [Related]
35. Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers.
Carson C; Shabsigh R; Segal S; Murphy A; Fredlund P; Kuepfer C;
Urology; 2005 Feb; 65(2):353-9. PubMed ID: 15708052
[TBL] [Abstract][Full Text] [Related]
36. The safety profile of tadalafil as prescribed in general practice in England: results from a prescription-event monitoring study involving 16 129 patients.
Hazell L; Cornelius V; Wilton LV; Shakir SA
BJU Int; 2009 Feb; 103(4):506-14. PubMed ID: 18990133
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular effects of tadalafil.
Kloner RA; Mitchell M; Emmick JT
Am J Cardiol; 2003 Nov; 92(9A):37M-46M. PubMed ID: 14609622
[TBL] [Abstract][Full Text] [Related]
38. Asenapine pharmacokinetics in hepatic and renal impairment.
Peeters P; Bockbrader H; Spaans E; Dogterom P; Lasseter K; Marbury T; Gibson GL; de Greef R
Clin Pharmacokinet; 2011 Jul; 50(7):471-81. PubMed ID: 21651314
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies.
Tomkinson H; Kemp J; Oliver S; Swaisland H; Taboada M; Morris T
BMC Clin Pharmacol; 2011 Mar; 11():3. PubMed ID: 21414193
[TBL] [Abstract][Full Text] [Related]
40. Likelihood of tadalafil-associated adverse events in integrated multiclinical trial database: classification tree analysis in men with erectile dysfunction.
Brock G; Glina S; Moncada I; Watts S; Xu L; Wolka A; Kopernicky V
Urology; 2009 Apr; 73(4):756-61. PubMed ID: 19193420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
